Peer-influenced content. Sources you trust. No registration required. This is HCN.

ReachMDKeeping Pace in Hematologic Malignancies: 2023 Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes (CME)

A 3-chapter, 0.50 credit, 30-minute multiplatform education program.

The landscape of AML treatment is evolving, thanks to advances in molecular profiling, classification, and emerging treatments. As medical professionals, the call to adapt our approaches to these changes is both exciting and challenging. In this unique CME program, we delve into these complexities, led by esteemed experts Drs. Harry Erba and Courtney DiNardo.

  • Discussion to focus on recent advances in molecular profiling, classification of AML, and emerging treatments
  • Objective to enhance diagnostic strategies, develop biomarker-driven treatment plans, and integrate combination regimens for deep remission
  • Target audience includes hematology oncologists, medical oncologists, oncology nurses, nurse practitioners, pathologists, radiation oncologists, pharmacists, physician assistants, and other HCPs treating patients with AML
  • The program is accredited by Global Learning Collaborative (GLC), offering 0.50 AMA PRA Category 1 Credits™, 0.5 nursing contact hours, and 0.50 AAPA Category 1 CME credits

Clinical Pharmacology Latest Posts

Did You Know?
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form